10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off
10x Genomics, Inc. — a leading player in single-cell and spatial biology — is back in the spotlight after a sharp share-price drop on 11 December 2025. A high-profile analyst downgrade from Citigroup hit the stock the same morning, even as the company pushes forward with ambitious AI collaborations and cancer atlas projects that could shape its long-term growth story. MarketScreener+2StockStory+2